Background: The immature fragile skin of preterm infants represents an inadequate protective barrier. The emollient and anti-infective properties of coconut oil make it a potentially beneficial topical agent for this population. Objectives: Our aim was to evaluate feasibility, safety, and the effects of topical coconut oil on skin condition in very preterm infants. Methods: An open-label randomised controlled trial in preterm infants <30 weeks' gestation was conducted. Enrolled infants were randomised to receive either routine care or topical coconut oil (5 mL/kg) twice daily for 21 days, starting within 24 h of birth. The neonatal skin condition was the primary outcome, and was assessed using the Neonatal Skin Condition Score (NSCS) on days 1, 7, 14, and 21. The number of coconut oil applications was recorded to assess clinical feasibility and all enrolled infants were monitored for adverse effects of topical coconut application, such as skin irritation. Results: A total of 72 infants born <30 weeks' gestation were enrolled (36 infants per arm), with comparable demographic characteristics. Topical application of coconut oil was feasible and without adverse effects. The NSCS was maintained in the coconut oil group throughout the intervention period, but deteriorated from a median (IQR) of 3 (3-4) on day 1 to 4 (4-4) on day 21 in the control group (p = 0.01). There were no differences in common neonatal outcomes, including sepsis, necrotising enterocolitis, retinopathy of prematurity, chronic lung disease, and mortality. Conclusions: Topical coconut oil maintained a better skin condition in very preterm infants without adverse effects. This simple, safe, and affordable intervention warrants further investigation.

1.
Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, Kennedy KA, Poindexter BB, Finer NN, Ehrenkranz RA, Duara S, Sanchez PJ, O'Shea TM, Goldberg RN, Van Meurs KP, Faix RG, Phelps DL, Frantz ID 3rd, Watterberg KL, Saha S, Das A, Higgins RD: Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443-456.
2.
Kalia YN, Nonato LB, Lund CH, Guy RH: Development of skin barrier function in premature infants. J Invest Dermatol 1998;111:320-326.
3.
Lund C, Kuller J, Lane A, Lott JW, Raines DA: Neonatal skin care: the scientific basis for practice. J Obstet Gynecol Neonatal Nurs 1999;28:241-254.
4.
Hammarlund K, Nilsson GE, Oberg PA, Sedin G: Transepidermal water loss in newborn infants. II. Relation to activity and body temperature. Acta Paediatr Scand 1979;68:371-376.
5.
Zutavern A, von Klot S, Gehring U, Krauss-Etschmann S, Heinrich J: Pre-natal and post-natal exposure to respiratory infection and atopic diseases development: a historical cohort study. Respir Res 2006;7:81.
6.
Salam RA, Darmstadt GL, Bhutta ZA: Effect of emollient therapy on clinical outcomes in preterm neonates in Pakistan: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 2015;100:F210-F215.
7.
Salam RA, Das JK, Darmstadt GL, Bhutta ZA: Emollient therapy for preterm newborn infants - evidence from the developing world. BMC Public Health 2013;13(suppl 3):S31.
8.
Darmstadt GL, Ahmed S, Ahmed AS, Saha SK: Mechanism for prevention of infection in preterm neonates by topical emollients: a randomized, controlled clinical trial. Pediatr Infect Dis J 2014;33:1124-1127.
9.
Darmstadt GL, Saha SK: Traditional practice of oil massage of neonates in Bangladesh. J Health Popul Nutr 2002;20:184-188.
10.
Fernandez A, Patkar S, Chawla C, Taskar T, Prabhu SV: Oil application in preterm babies - a source of warmth and nutrition. Indian Pediatr 1987;24:1111-1116.
11.
Duffy JL, Ferguson RM, Darmstadt GL: Opportunities for improving, adapting and introducing emollient therapy and improved newborn skin care practices in Africa. J Trop Pediatr 2012;58:88-95.
12.
Yurdakok M, Yurdakok K: Topical vegetable oil therapy for premature infants. J Pediatr 1997;130:330-332.
13.
Cleminson J, McGuire W: Topical emollient for prevention of infection in preterm infants: a systematic review. Lancet 2015;385(suppl 1):S31.
14.
Carpo BG, Verallo-Rowell VM, Kabara J: Novel antibacterial activity of monolaurin compared with conventional antibiotics against organisms from skin infections: an in vitro study. J Drugs Dermatol 2007;6:991-998.
15.
Batovska DI, Todorova IT, Tsvetkova IV, Najdenski HM: Antibacterial study of the medium chain fatty acids and their 1-monoglycerides: individual effects and synergistic relationships. Pol J Microbiol 2009;58:43-47.
16.
Fischer CL, Blanchette DR, Brogden KA, Dawson DV, Drake DR, Hill JR, Wertz PW: The roles of cutaneous lipids in host defense. Biochim Biophys Acta 2014;1841:319-322.
17.
Ogbolu DO, Oni AA, Daini OA, Oloko AP: In vitro antimicrobial properties of coconut oil on Candida species in Ibadan, Nigeria. J Med Food 2007;10:384-387.
18.
Nakatsuji T, Kao MC, Fang JY, Zouboulis CC, Zhang L, Gallo RL, Huang CM: Antimicrobial property of lauric acid against Propionibacterium acnes: its therapeutic potential for inflammatory acne vulgaris. J Invest Dermatol 2009;129:2480-2488.
19.
Lund CH, Osborne JW: Validity and reliability of the Neonatal Skin Condition Score. J Obstet Gynecol Neonatal Nurs 2004;33:320-327.
20.
Darmstadt GL, Badrawi N, Law PA, Ahmed S, Bashir M, Iskander I, Al Said D, El Kholy A, Husein MH, Alam A, Winch PJ, Gipson R, Santosham M: Topically applied sunflower seed oil prevents invasive bacterial infections in preterm infants in Egypt: a randomized, controlled clinical trial. Pediatr Infect Dis J 2004;23:719-725.
21.
Australian Government National Health and Medical Research Council: Joint NHMRC/AVCC statement and guidelines on research practice. Canberra, NHMRC, 2015.
22.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG: Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-381.
23.
Edwards WH, Conner JM, Soll RF; Vermont Oxford Network Neonatal Skin Care Study Group: The effect of prophylactic ointment therapy on nosocomial sepsis rates and skin integrity in infants with birth weights of 501 to 1000 g. Pediatrics 2004;113:1195-1203.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.